ENTERA BIO LTD.

Analyst Reco. Entera Bio Ltd.

Equities

ENTX

IL0011429839

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
2.25 ^USD	-3.02%		-5.86%	+275.00%

May. 15	Entera Bio Appoints Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member	CI
May. 13	Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets for the Treatment of Hypoparathyroidism at ENDO 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Initiates Entera Bio at Buy With $10 Price Target	22-09-06	MT
B. Riley Securities Trims Entera Bio's Price Target to $5 from $6 to Reflect Delayed Clinical/Regulatory Path, Keeps Buy Rating	22-07-19	MT
Maxim Group Adjusts Entera Bio Price Target to $6 From $10, Maintains Buy Rating	22-02-02	MT
B. Riley Lowers Entera Bio's Price Target to $6 from $11 After Revising Cost Capital Assumptions, Keeps Buy Rating	22-01-24	MT
ENTERA BIO : B. Riley Lowers Entera Bio's PT to $11 from $14 Following Results from Phase II Study of EB613 Osteoporosis Treatment, Keeps Buy Rating	21-10-07	MT
ENTERA BIO : B. Riley Raises Entera Bio's PT to $14 from $9 After Encouraging Clinical Results of EB613 Study, Keeps Buy Rating	21-06-24	MT
ENTERA BIO : B. Riley Starts Entera Bio at Buy with $9 PT, Notes Lead Program's Potential to be First Oral Osteoanabolic Product to Treat Osteoporosis	21-06-16	MT
ENTERA BIO : Aegis Capital Initiates Entera Bio at Buy Rating With $12 Price Target	21-03-22	MT
ENTERA BIO : Maxim Adjusts Price Target on Entera Bio to $10 From $5, Maintains Buy Rating	21-03-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer